Shares of AstraZeneca PLC (AZN) surged 5.03% in pre-market trading on Thursday, following the company's impressive fourth-quarter results and optimistic guidance for 2025.
AstraZeneca reported a 24% year-over-year increase in total revenue for Q4 2024, reaching $14.89 billion, driven by robust growth across its key therapy areas, including Oncology (up 27%), Cardiovascular, Renal, and Metabolism (CVRM, up 16%), and Respiratory & Immunology (R&I, up 27%). The company's core earnings per share (EPS) jumped 44% to $2.09, surpassing analysts' expectations.
For the full year 2024, AstraZeneca's total revenue grew 21% to $54.07 billion, while core EPS increased 19% to $8.21. The strong performance was fueled by a 19% rise in product sales, continued growth in partnered medicines (Alliance Revenue), and the achievement of sales-based milestones (Collaboration Revenue).
Looking ahead, AstraZeneca provided an optimistic guidance for 2025, forecasting a high single-digit percentage increase in total revenue and a low double-digit percentage growth in core EPS, both at constant exchange rates. The company also announced plans to increase its annual dividend to $3.20 per share and boost capital expenditure by approximately 50% to support portfolio growth and build capacity for transformative technologies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。